Storing solar and wind energy to meet the increasing power needs of the electrical grid calls for devices that can deliver ...

The NFL offseason continues to trudge along as free agency has made it through its first week, and the Green Bay Packers have been able to add to their roster, as they typically have done under Brian ...

SAN JOSE, California – It’s finally here, the chip that Nvidia CEO Jensen Huang claimed would “surprise people” at GTC was revealed: Nvidia Groq 3 LPU. The chip, or a language processing unit (LPU), ...

March 3 (Reuters) - British investor Rosebank Industries (ROSE.L), opens new tab said on Tuesday it would buy two ‌U.S.-based industrial businesses, MW Components and CPM, in a deal worth $3.05 ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

Google announced Gemini 3, an upgraded artificial intelligence model, almost eight months after the company rolled out Gemini 2.5. The company said its latest suite of AI models will require users to ...

Here’s a challenge: take $3 million in available cash and turn it into a machine that creates $250,000 worth of income per year. Not long ago, a Reddit user posed this challenge, asking what would be ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...

What Is Empaveli, and Why Does It Matter? First approved in 2021 for a rare blood disorder, Empaveli (pegcetacoplan) is now approved as the first targeted medicine for adults and children aged 12 ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...